These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1945 related articles for article (PubMed ID: 20219512)

  • 1. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic investigation of signatures for geniposide-induced hepatotoxicity.
    Wei J; Zhang F; Zhang Y; Cao C; Li X; Li D; Liu X; Yang H; Huang L
    J Proteome Res; 2014 Dec; 13(12):5724-33. PubMed ID: 25336395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans?
    Zhang M; Chen M; Tong W
    Chem Res Toxicol; 2012 Jan; 25(1):122-9. PubMed ID: 22122743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity.
    Van Summeren A; Renes J; van Delft JH; Kleinjans JC; Mariman EC
    Toxicol In Vitro; 2012 Apr; 26(3):373-85. PubMed ID: 22274661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies.
    Adler M; Hoffmann D; Ellinger-Ziegelbauer H; Hewitt P; Matheis K; Mulrane L; Gallagher WM; Callanan JJ; Suter L; Fountoulakis MM; Dekant W; Mally A
    Toxicol Lett; 2010 Jun; 196(1):1-11. PubMed ID: 20362651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies.
    Amacher DE
    Toxicology; 2011 Jan; 279(1-3):10-8. PubMed ID: 20974209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted mass spectrometry approaches for protein biomarker verification.
    Meng Z; Veenstra TD
    J Proteomics; 2011 Nov; 74(12):2650-9. PubMed ID: 21540133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical safety assessment: current gaps, challenges, and approaches in identifying translatable biomarkers of drug-induced liver injury.
    Ramaiah SK
    Clin Lab Med; 2011 Mar; 31(1):161-72. PubMed ID: 21295728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of biomarker development on drug safety assessment.
    Marrer E; Dieterle F
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):167-79. PubMed ID: 20036272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring.
    Muller PY; Dieterle F
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1023-38. PubMed ID: 19611406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass spectrometry-based biomarkers in drug development.
    Miller RA; Spellman DS
    Adv Exp Med Biol; 2014; 806():341-59. PubMed ID: 24952191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent successes in the identification, development, and qualification of translational biomarkers: the next generation of kidney injury biomarkers.
    Ennulat D; Adler S
    Toxicol Pathol; 2015 Jan; 43(1):62-9. PubMed ID: 25492424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies.
    Donato MT; Gómez-Lechón MJ; Tolosa L
    Expert Opin Drug Discov; 2017 Feb; 12(2):201-211. PubMed ID: 27936962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety biomarkers in preclinical development: translational potential.
    Sasseville VG; Mansfield KG; Brees DJ
    Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity.
    Beger RD; Sun J; Schnackenberg LK
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):154-66. PubMed ID: 19932708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 98.